Key facts
- This page summarizes Jonathan Schechter's Form 4 filing for PharmaCyte Biotech, Inc. (PMCB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Apr 2026, 18:17.
Jonathan Schechter - 31 Mar 2026 Form 4 Insider Report for PharmaCyte Biotech, Inc. (PMCB)
- Reporting relationship
- Director
- Issuer ticker
- PMCB
- Reported as of
- 31 Mar 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Apr 2026, 18:17:06 UTC
- Prior SEC filing
- 07 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Schechter
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Schechter filed Form 4 for PharmaCyte Biotech, Inc. (PMCB) on 02 Apr 2026.
Change
- Previous filing in this sequence was filed on 07 Jan 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001619259
Primary reporting owner
SCHECHTER JONATHAN
- Relationship
- Director
- Address
- C/O PHARMACYTE BIOTECH, INC., 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS
- Signature
- /s/ Jonathan Schechter
- Signature date
- 02 Apr 2026
This filing has been restated.
Open the amended filing.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PMCB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +119,170
- Change %
- Price
- $0.000000*
- Shares after
- 119,170
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 119,170
- Exercise price
- $0.6700
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter.